Recent developments include increased sales in pharmaceuticals and cosmetic/sexual wellness ingredients in early 2026, a new distribution agreement for sexual wellness products, and continued dividend payments.

• United-Guardian declared a cash dividend continuing a 30-year streak, with $0.25 per share declared in early 2026 [N1].
• Q1 2026 earnings rose year-over-year driven by strong demand for Renacidin, the company’s key pharmaceutical product [N3].
• Q1 2026 profit advanced reflecting operational improvements [N4].
• The company’s 2025 earnings fell year-over-year amid weak sales trends, particularly in cosmetics [N7].
• Q2 2025 earnings declined year-over-year due to weak cosmetic sales offset partially by pharmaceutical gains [N8].
• In January 2026, United-Guardian entered a new distribution agreement with Brenntag Specialties for sexual wellness products in North America and France, marking the start of sales in this segment [S2].
• Sales of cosmetic and sexual wellness ingredients increased significantly in Q2 2026 compared to Q2 2025, driven by resumed orders from major distributors [S2].
• Sales of medical lubricants decreased in Q2 2026 due to reduced orders from the largest customer in India [S2].
• The company received a settlement from its contract manufacturer related to a shutdown in 2023-2024, resulting in product supplied at no cost valued at approximately $339,493 in 2026 [S2].

The company’s diversified product portfolio across cosmetics, pharmaceuticals, medical lubricants, and sexual wellness ingredients provides multiple growth avenues. Recent distribution agreements, especially for the Natrajel line, open new markets. The inclusion of Renacidin on major pharmacy benefit manager formularies enhances market access. Strong liquidity and consistent dividend payments reflect financial stability. Continued product innovation and expansion into natural and sustainable products align with consumer trends.

United-Guardian faces pricing pressure from low-cost competitors in the cosmetic ingredients market. Sales declines in medical lubricants due to reduced orders from a major customer highlight customer concentration risks. The company relies on a single contract manufacturer for Renacidin, posing supply chain risk. Market penetration of new sexual wellness products is nascent, with limited sales to date. Customer and distributor concentration could impact revenue stability. Global supply chain disruptions and trade policy changes may affect raw material availability and costs.

United-Guardian’s moat is supported by its product innovation capabilities, proprietary formulations protected as trade secrets, and established distribution partnerships globally. Its Renacidin pharmaceutical product holds a unique position as the only FDA-approved drug for its indication, providing a competitive advantage. The company’s focus on natural and certified products aligns with growing market demand, and its reliable supply chain and technical expertise contribute to customer loyalty and market resilience.

• Customer and Distributor Concentration: A significant portion of sales and accounts receivable is concentrated among a few distributors and wholesalers, which could impact revenue if relationships change.
• Supply Chain Dependence: Renacidin is manufactured by a single contract manufacturer; disruptions could materially affect product availability and sales.
• Competitive Pricing Pressure: The cosmetic ingredients market faces pricing pressure from low-cost competitors, which may affect margins and market share.
• Market Adoption of New Products: The sexual wellness product line is newly launched with limited sales, and market acceptance is uncertain.
• Regulatory and Trade Risks: Changes in trade policies, tariffs, and regulatory requirements could disrupt supply chains and increase costs.

• United-Guardian, Inc. is a Delaware corporation operating through its Guardian Laboratories division, manufacturing, marketing, and developing specialty cosmetic, personal care, sexual wellness ingredients, and healthcare products including pharmaceuticals and medical lubricants [S1].
• The company conducts R&D focused on new and unique specialty cosmetic and sexual wellness ingredients, emphasizing natural and environmentally friendly raw materials [S1].
• All products except Renacidin are produced at the Hauppauge, New York facility; Renacidin is manufactured by an outside contract manufacturer [S1].
• United-Guardian operates as a single business segment with four product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients, each marketed differently [S1].
• Cosmetic ingredients include the Lubrajel line of multifunctional hydrogel formulations used in personal care products, with a focus on natural and sustainable products certified by COSMOS [S1].
• Medical lubricants are also sold under the Lubrajel brand, used in catheters, surgical instruments, oral care, condoms, and medical devices, sold directly to manufacturers and marketers [S1].
• Pharmaceutical products include Renacidin, an FDA-approved prescription drug for preventing and dissolving calcifications in urethral catheters, and Clorpactin, a chlorine-based topical antimicrobial [S1].
• Pharmaceutical products are sold primarily to three national full-line drug wholesalers supplying pharmacies, hospitals, and government agencies; sales are final when shipped with limited return rights [S1].
• Sexual wellness ingredients include a new Natrajel line of hydrogel formulations for sensory enhancement and lubrication, with distribution agreements initiated in 2026 [S1, S2].
• In January 2026, United-Guardian entered a distribution agreement with Brenntag Specialties for Natrajel products in the US, Canada, Mexico, and France, marking the start of sexual wellness product sales [S2].
• The company’s largest cosmetic ingredient distributor is Ashland Specialty Ingredients (ASI), which resumed normal purchasing in 2026 after an overstock situation in 2025 [S2].
• Sales trends in 2026 show increased net sales in pharmaceuticals and cosmetic/sexual wellness ingredients, with decreased sales in medical lubricants due to reduced orders from a major customer in India [S2].
• The company has a history of paying dividends, including a $0.25 per share cash dividend declared in early 2026, continuing a long-standing dividend policy [N1, S2].
• United-Guardian’s financial snapshot as of June 30, 2026, includes cash and equivalents of $2.39 million, current assets of $12.7 million, current liabilities of $1.74 million, resulting in a current ratio of 7.32 and a cash ratio of 5.82, indicating strong liquidity [S2].
• Net income for the quarter ended June 30, 2026, was $728,579 with basic EPS of $0.16 [S2].
• The company received a settlement from its contract manufacturer related to a shutdown in 2023-2024, resulting in product supplied at no cost valued at approximately $339,493 in 2026 [S2].
• United-Guardian’s product innovation and formulation expertise are central to maintaining market position and pursuing growth, with a focus on unmet market needs and unique product properties [S1].
• The company’s products are marketed globally through a network of distributors and direct sales, with multiple distributors covering different geographic regions [S1].
• The company faces competition primarily based on product performance, price, quality, service, availability, and innovation, with some competitors larger and more resourceful [S1].
• Renacidin has no direct competition as the only FDA-approved drug for its indication [S1].
• The company’s financial policies include maintaining sufficient working capital and liquidity to support operations and growth, with no off-balance-sheet arrangements [S2, S14].
• United-Guardian’s effective income tax rate was approximately 21% for 2026 [S2].
• The company’s sales are concentrated with a few distributors and wholesalers, representing a significant portion of gross sales and accounts receivable [S19].
• The company’s credit risk is managed through customer credit evaluations and monitoring, with historically low credit losses [S19].